Hôpital Pontchaillou

Running trials

• Not yet recruiting

  "Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis

  NCT07889726· University Hospital, Toulouse· Source

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

  NCT06487078· Pfizer· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Active, not recruiting

  Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

  NCT06353022· Phase 2· Nantes University Hospital· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Recruiting

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

  NCT05689151· Pfizer· Source

• Active, not recruiting

  Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

  NCT04475393· Carmat SAS· Source

• Active, not recruiting

  French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

  NCT05590702· French Innovative Leukemia Organisation· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Recruiting

  Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years

  NCT05373940· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

  NCT04968015· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy

  NCT04994665· Centre Hospitalier Departemental Vendee· Source

• Recruiting

  National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

  NCT04166266· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  French Registry for Monitoring Pregnancies for Multiple Sclerosis

  NCT03900221· Hospices Civils de Lyon· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure2 recruiting
• Lung cancer2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver cirrhosis1 recruiting
• Multiple sclerosis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

  NCT04992949· Phase 2· French Innovative Leukemia Organisation· Source

• Completed

  BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

  NCT04827719· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Daiichi Sankyo· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Theravia· Source

• Completed

  Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

  NCT03808805· Phase 3· University Hospital, Brest· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Groupe Francophone des Myelodysplasies· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source